Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition